Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients.

BACKGROUND Priming of the polymorphonuclear neutrophil (PMN) response has been implicated in the activation of oxidative burst and tissue injury in patients with septic shock and acute renal failure (ARF). This study evaluated whether hemofiltration (HF) removes substances able to enhance the oxidative burst of PMNs. METHODS Chemiluminescence (CL) priming activity induced by sera and ultrafiltrates of seven patients with septic shock, multiorgan dysfunction syndrome, and ARF (ARF/HF group) and of 10 uremic stable patients (Control/HF group) was evaluated on normal human PMNs stimulated with bacterial formyl-methionyl-leucyl-phenylalanine (FMLP). Patients submitted to HF were studied by determining blood and ultrafiltrate interleukin-8 (IL-8), platelet-activating factor (PAF), and CL priming activity at the beginning (T0), and after four hours (T4) of treatment. RESULTS Preincubation of normal human PMNs with sera and ultrafiltrates from septic patients induced a potent priming of CL activity in subsequent FMLP stimulation. In the ARF/HF group, the prefilter blood concentrations of IL-8 and CL PMN-priming activity significantly decreased during the four hours of HF treatment, with a loss of IL-8 in the ultrafiltrate of 6930 (median, range 4292 to 9282) ng per four hours. PAF detected in the ultrafiltrate and associated with the membrane (7.3 ng, range 1.45 to 9.89) was minimal. In the ARF/HF group, a significantly positive correlation between CL PMN-priming activity and IL-8 concentrations was observed. The CL priming activity in blood and ultrafiltrates was reduced to 55 and 46% by preabsorption with monoclonal antibody (mAb) anti-IL-8. In contrast, the PAF receptor antagonist WEB 2170 did not affect CL priming activity. In the control/HF group, the CL PMN-priming activity was significantly lower than in the ARF/HF group and was independent of IL-8. CONCLUSIONS Sera from septic patients demonstrate an enhanced CL priming activity on PMNs. This activity is reduced by ultrafiltration and is due, at least in part, to ultrafiltered IL-8.

[1]  G. Camussi,et al.  Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.

[2]  M. Yaffe,et al.  Priming of the neutrophil respiratory burst is species-dependent and involves MAP kinase activation. , 1999, Surgery.

[3]  R. Bellomo,et al.  Continuous renal replacement therapy in the intensive care unit , 1999, Intensive Care Medicine.

[4]  G. Camussi,et al.  Production of platelet-activating factor in patients with sepsis-associated acute renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  J. De Sutter,et al.  Cytokine removal during continuous hemofiltration in septic patients. , 1999, Journal of the American Society of Nephrology : JASN.

[6]  John P. Johnson,et al.  Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. , 1998, Critical care medicine.

[7]  J. Cavaillon,et al.  Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. , 1998, Blood.

[8]  W. Silvester,et al.  Mediator removal with CRRT: complement and cytokines. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  C. Ronco,et al.  Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Lamy,et al.  Sepsis and serum cytokine concentrations. , 1997, Critical care medicine.

[11]  J. Cavaillon,et al.  Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome , 1997, Infection and immunity.

[12]  C. Haslett,et al.  Demonstration of reversible priming of human neutrophils using platelet-activating factor. , 1996, Blood.

[13]  F. A. Moore,et al.  Sequential systemic platelet‐activating factor and interleukin 8 primes neutrophils in patients with trauma at risk of multiple organ failure , 1996, The British journal of surgery.

[14]  D. Inthorn,et al.  Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. , 1995, Contributions to nephrology.

[15]  G. Camussi,et al.  Septic shock--the unravelling of molecular mechanisms. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  E. Moore,et al.  Postinjury neutrophil priming and activation: an early vulnerable window. , 1995, Surgery.

[17]  E. Moore,et al.  The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. , 1994, The Journal of trauma.

[18]  S. Goldfarb,et al.  Proinflammatory cytokines and hemofiltration membranes. , 1994, Journal of the American Society of Nephrology : JASN.

[19]  C. Elbim,et al.  Differential priming effects of proinflammatory cytokines on human neutrophil oxidative burst in response to bacterial N-formyl peptides , 1994, Infection and immunity.

[20]  R. Taylor,et al.  Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis , 1994, Critical care medicine.

[21]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[22]  W. H. Betts,et al.  Interleukin-8 primes human neutrophils for enhanced superoxide anion production. , 1993, Immunology.

[23]  M. Baggiolini,et al.  Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst 1 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  R. Bellomo,et al.  Continuous veno‐venous hemofiltration with dialysis removes cytokines from the circulation of septic patients , 1993, Critical care medicine.

[25]  G. Camussi,et al.  Role of α1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients , 1992 .

[26]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[27]  K. Matsushima,et al.  Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. , 1991, Blood.

[28]  H. Heuer,et al.  Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. , 1990, The Journal of pharmacology and experimental therapeutics.

[29]  P. Henson,et al.  Binding of platelet activating factor to albumin. , 1990, Biochimica et biophysica acta.

[30]  W. Hörl,et al.  Neutrophil activation in acute renal failure and sepsis. , 1990, Archives of surgery.

[31]  P. Sole Polymorphonuclear chemiluminescence: Some clinical applications , 1989 .

[32]  J. Larrick,et al.  Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. , 1987, Journal of immunology.

[33]  J. Lukens,et al.  Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. , 1986, Blood.

[34]  B. Dewald,et al.  Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4. , 1985, Biochemical and biophysical research communications.

[35]  H. Nomura,et al.  CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.

[36]  J. Benveniste,et al.  Structural analysis of purified platelet-activating factor by lipases , 1977, Nature.

[37]  R. Allen Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. , 1986, Methods in enzymology.